Kala Bio, Inc. (KALA): Depreciation & Amortization
$317.0K
Year ended 2025-12-31
-16.1%
3-year compound annual growth
-19.1%
5-year compound annual growth
| Period ended | Depreciation & Amortization | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $317.0K | +22.4% | 2026-04-15, From 2025-01-01 |
| 2024-12-31 | $259.0K | -14.5% | 2026-04-15, From 2024-01-01 |
| 2023-12-31 | $303.0K | -43.6% | 2025-03-31, From 2023-01-01 |
| 2022-12-31 | $537.0K | -44.9% | 2024-03-29, From 2022-01-01 |
| 2021-12-31 | $975.0K | +6.9% | 2023-03-03, From 2021-01-01 |
| 2020-12-31 | $912.0K | +8.2% | 2022-03-29, From 2020-01-01 |
| 2019-12-31 | $843.0K | n/a | 2021-02-25, From 2019-01-01 |
Depreciation & Amortization at similar companies
| Company | Year ended | Depreciation & Amortization | Change YoY |
|---|---|---|---|
| Kala Bio, Inc. (KALA) | 2025-12-31 | $317.0K | +22.4% |
| Bristol Myers Squibb Co (BMY) | 2025-12-31 | $4.01B | -58.2% |
| TherapeuticsMD, Inc. (TXMD) | 2025-12-31 | $384.0K | -24.6% |
| Eli Lilly & Co (LLY) | 2025-12-31 | $2.00B | +13.0% |
| Pfizer Inc (PFE) | 2025-12-31 | $6.59B | -6.0% |
| Johnson & Johnson (JNJ) | 2025-12-28 | $7.50B | +2.2% |
| Nature's Sunshine Products Inc (NATR) | 2025-12-31 | $13.84M | -2.6% |
| Lisata Therapeutics, Inc. (LSTA) | 2025-12-31 | $146.0K | -16.1% |
| Heron Therapeutics, Inc. (HRTX) | 2025-12-31 | $2.31M | -7.1% |
Compare KALA, BMY, TXMD, LLY side by side · Screen every company in Pharmaceutical Preparations ↗